Skip to content

The influence of the prognosis of increasing the antiplatelet therapy of the patient of ACS before PCI

To explore the effectiveness and security of ticagrelor and bivalirudin

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16009179
Enrollment
Unknown
Registered
2016-09-10
Start date
2016-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Interventions

1:Bivalirudin + ticagrelor + aspirin
2:Ticagrelor + aspirin + heparin
3:Aspirin + clopidogrel + aspirin
4:Heparin + clopidogrel + aspirin

Sponsors

The second hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
19 Years to 79 Years

Inclusion criteria

Inclusion criteria: (1) aged 18 to 80 years; (2) all consecutive patients were diagnosed with ACS, including UA, STEMI and NSTEMI;

Exclusion criteria

Exclusion criteria: (1) long term warfarin therapy; (2) hemorrhagic tendency including alimentary tract hemorrhage in 3 month,cerebral hemorrhage in 6 month and cerebral infraction;be in peptic ulcer activity; (3) severe neutropenia and thrombocytopenia or having the heparin induced thrombocytopenia history; (4) the index of liver and kidney function is higher than ULN 1-5 times (except the myocardial infarction resulted in the high liver function index); (5) there were deep puncture and major surgery in 1 month; (6) allergy to heparin or biological products; (7) applying the tirofiban in the operation; (8) pregnant women and women with breast feeding or birth control program.

Design outcomes

Primary

MeasureTime frame
Comparison of major cardiovascular events;

Countries

China

Contacts

Public ContactWang Mei

The second hospital of Hebei Medical University

wangmei86632@sina.com+86 15803217657

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026